Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

L Blackwell, Kimberly; J Burstein, Harold; Maria Storniolo, Anna; Rugo, Hope; Sledge, George; Koehler, Maria; Ellis, Catherine; Casey, Michelle; Vukelja, Svetislava; Bischoff, Joachim; Baselga, Jose; O'Shaughnessy, Joyce

doi:10.1200/jco.2008.21.4437

Public

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Published in Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Mar 1, 2010

NobleIDark:/48914/w1/20260526/901BB0C9Record on NobleID

Authors:

Kimberly L Blackwell

,

Harold J Burstein

,

Anna Maria Storniolo

Abstract

PURPOSE: Preclinical studies in ErbB2-positive cell lines demonstrated a synergistic interaction between lapatinib and trastuzumab, suggesting that dual blockade is more effective than a single agent alone. EGF104900 compared the activity of lapatinib alone or in combination with trastuzumab in pati...

Discussions